Dobutamine

How to use it (ICU/OT practical)

Indication-led choice: use when you need to increase cardiac output via inotropy (e.g. low-output states) and SVR is not critically low.
- If profound vasodilation/hypotension is dominant, consider adding/using a vasopressor (e.g. noradrenaline) rather than escalating dobutamine alone.
Starting infusion: 2.5–5 micrograms/kg/min; titrate to effect (commonly 2.5–20 micrograms/kg/min).
- Higher doses increase risk of tachyarrhythmias and myocardial ischaemia; aim for the lowest dose achieving perfusion targets.
Targets to titrate against: MAP, urine output, lactate trend, ScvO2/SvO2, echo-derived stroke volume/CO, capillary refill and peripheral perfusion.
Administration: central line preferred (vasoactive infusion); dedicated lumen; use an infusion pump; continuous ECG and BP monitoring.
Weaning: reduce gradually once perfusion stable and underlying cause treated; avoid abrupt cessation in dependent low-output states.

Common clinical scenarios

Acute decompensated heart failure/cardiogenic shock with low output (often with vasopressor support if hypotensive).
Post-cardiac surgery low cardiac output syndrome; RV dysfunction (may help but consider pulmonary vasodilators if PVR high).
- Dobutamine can reduce PVR modestly via beta-2 effects, but tachycardia may worsen RV ischaemia.
Septic shock with myocardial depression (low EF/low stroke volume) after adequate fluid resuscitation and with vasopressor to maintain MAP.
Stress echocardiography (pharmacological stress test).

Drug class and presentation

Synthetic catecholamine; predominantly beta-adrenergic agonist with inotropic effects.
Given IV as continuous infusion; not effective orally (rapid metabolism).

Mechanism of action

Primarily stimulates cardiac beta-1 receptors → ↑ adenylate cyclase → ↑ cAMP → ↑ intracellular Ca2+ availability → ↑ contractility and (to a lesser extent) ↑ HR.
Some beta-2 agonism → peripheral vasodilation (↓ SVR) and mild pulmonary vasodilation (↓ PVR).
Net effect is dose- and patient-dependent; in many patients CO rises with little change or a fall in SVR.

Receptor profile (exam-friendly)

Predominantly beta-1 agonist; also beta-2 agonist; minimal alpha effects at usual doses.
- Clinical translation: strong inotropy with less vasoconstriction than adrenaline/noradrenaline.

Haemodynamic effects

↑ Cardiac output mainly via ↑ stroke volume; HR may increase (less than with adrenaline/isoprenaline but clinically important).
↓ SVR (beta-2) → MAP may fall if CO does not rise sufficiently or if vasoplegia present.
May reduce LV filling pressures by improving forward flow; can worsen dynamic LVOT obstruction (e.g. HOCM) by increasing contractility.
Myocardial oxygen consumption increases (↑ inotropy/chronotropy) → risk of ischaemia in CAD.

Pharmacokinetics

Onset: 1–2 minutes; peak effect within ~10 minutes after dose change.
Half-life: ~2 minutes (very short), hence rapid titratability.
Metabolism: mainly by catechol-O-methyltransferase (COMT) and conjugation; metabolites excreted in urine.

Adverse effects

Tachycardia and tachyarrhythmias (atrial fibrillation, SVT, ventricular ectopy).
Myocardial ischaemia/infarction due to increased oxygen demand and reduced diastolic time (tachycardia).
Hypotension from beta-2 vasodilation, especially in vasoplegia or hypovolaemia.
Electrolyte/metabolic: may cause hypokalaemia (beta-2 mediated intracellular shift), hyperglycaemia (less prominent than adrenaline).
Tolerance/tachyphylaxis can occur with prolonged infusion (beta receptor downregulation).

Contraindications and cautions

Caution in: ischaemic heart disease, tachyarrhythmias, hypertrophic obstructive cardiomyopathy (can worsen LVOT obstruction), severe hypovolaemia (may worsen hypotension).
In atrial fibrillation with rapid ventricular response: may accelerate rate; treat rate and consider alternative strategy.
Beta-blockade: response may be blunted; consider alternative inotrope (e.g. phosphodiesterase inhibitor) depending on context and local practice.

Monitoring and endpoints

Continuous ECG, arterial BP (preferably invasive), clinical perfusion markers; consider echo/CO monitoring in shock states.
Watch for: rising HR, new ectopy, ST changes, falling MAP, worsening lactate, inadequate urine output.

Interactions

MAO inhibitors and tricyclic antidepressants can potentiate catecholamine effects (hypertension/arrhythmias).
Beta-blockers antagonise effects; non-selective beta-blockade may unmask alpha effects (less relevant for dobutamine than for adrenaline).
Halogenated volatile agents increase arrhythmogenicity with catecholamines (clinical relevance depends on dose and patient substrate).

Comparisons (high-yield)

Dobutamine vs dopamine: dobutamine is more predictable inotrope with less tachycardia at equivalent inotropic effect; dopamine has dose-dependent receptor effects and higher arrhythmia risk.
Dobutamine vs adrenaline: adrenaline provides inotropy plus vasoconstriction (alpha) and more metabolic effects (lactate, glucose); dobutamine tends to reduce SVR.
Dobutamine vs noradrenaline: noradrenaline is primarily a vasopressor (alpha) with some beta-1; combine if you need both MAP support and inotropy.

Describe dobutamine: class, mechanism, and main haemodynamic effects.

Structure your answer: class → receptors → second messenger → haemodynamics.

Class: synthetic catecholamine; IV inotrope.
Receptors: predominantly beta-1; some beta-2; minimal alpha at usual doses.
Mechanism: beta-1 → ↑ cAMP → ↑ intracellular Ca2+ → ↑ contractility (and some ↑ HR).
Haemodynamics: ↑ CO (mainly ↑ SV), HR may rise; ↓ SVR (beta-2) so MAP may fall if CO does not compensate; ↑ myocardial O2 demand.

You are asked: 'What dose would you start dobutamine at and how quickly does it work?'

Start 2.5–5 micrograms/kg/min; titrate to effect (commonly up to ~20 micrograms/kg/min).
Onset 1–2 minutes; peak effect within ~10 minutes after a dose change; half-life ~2 minutes.

Explain why dobutamine can cause hypotension in a shocked patient.

Beta-2 mediated vasodilation reduces SVR; if the patient is vasoplegic or underfilled, the fall in SVR may outweigh the CO increase → MAP drops.
Tachycardia can reduce diastolic filling time → stroke volume may not rise as expected, limiting CO response.
Management: correct hypovolaemia, add vasopressor (e.g. noradrenaline), reassess with echo/CO monitoring.

In septic shock, when would you consider adding dobutamine and what would you monitor?

Consider when there is evidence of myocardial depression/low cardiac output despite adequate fluid resuscitation and MAP supported with vasopressor.
Monitor: HR/rhythm, invasive BP, lactate clearance, urine output, ScvO2/SvO2, echo-derived stroke volume/CO, signs of ischaemia.
Be alert to: worsening hypotension (↓ SVR), tachyarrhythmias, rising lactate from ongoing shock (not necessarily drug effect).

List the important adverse effects of dobutamine and how you would mitigate them.

Tachycardia/arrhythmias: titrate slowly, correct electrolytes (K+, Mg2+), treat precipitating factors (pain, hypoxia), consider alternative inotrope if problematic.
Myocardial ischaemia: avoid excessive HR, maintain coronary perfusion pressure, treat anaemia/hypoxia, consider reducing dose or alternative support.
Hypotension: ensure adequate preload; add vasopressor; reassess diagnosis (e.g. tamponade, PE) with echo.

A previous FRCA-style question: 'Compare dobutamine with dopamine.'

Receptors: dobutamine mainly beta-1 (plus beta-2); dopamine has dose-dependent dopaminergic/beta/alpha effects (less predictable clinically).
Haemodynamics: dobutamine increases CO with tendency to reduce SVR; dopamine at higher doses increases SVR and HR more variably.
Adverse effects: dopamine associated with more tachyarrhythmias; dobutamine still arrhythmogenic but often preferred for inotropy.
Clinical use: dobutamine for low-output states; dopamine use has declined in many protocols due to arrhythmia risk and lack of renal-protective benefit.

A previous FRCA-style question: 'Why might dobutamine be a poor choice in hypertrophic obstructive cardiomyopathy (HOCM)?'

Increased contractility can worsen dynamic LVOT obstruction; tachycardia reduces filling time and LV volume, further increasing obstruction.
Preferred haemodynamic goals in HOCM: maintain preload, avoid tachycardia, maintain/increase afterload (vasoconstrictor), reduce contractility (beta-blocker).

A previous FRCA-style question: 'Outline the pharmacokinetics of dobutamine and the implications for infusion changes.'

Very short half-life (~2 minutes) with rapid onset; effects change quickly after dose adjustments.
Allow several minutes (up to ~10 minutes) to assess near-peak response after a change, using haemodynamic and perfusion endpoints.
Because it is rapidly metabolised (COMT), stopping the infusion leads to rapid offset—plan weaning and ensure alternative support if needed.

How would you manage a patient who becomes tachycardic and hypotensive after starting dobutamine?

Immediate assessment: rhythm (ECG), BP (arterial line if possible), signs of ischaemia, volume status, and underlying cause of shock.
Actions: reduce/stop dobutamine if causing harm; correct hypovolaemia; add vasopressor to restore SVR/MAP; treat arrhythmia (rate control/cardioversion as appropriate).
Reassess with bedside echo to exclude tamponade, severe LV dysfunction, RV failure/PE, dynamic LVOT obstruction.

What are the key monitoring requirements and safety considerations for dobutamine infusions in theatre/ICU?

Continuous ECG and frequent BP measurement (ideally invasive); monitor perfusion endpoints (urine output, lactate, mental state, peripheral perfusion).
Central venous access preferred; dedicated lumen; infusion pump; clear labelling and dose in micrograms/kg/min.
Regular review for arrhythmias/ischaemia and for need to add vasopressor if SVR falls.